News | December 13, 2022
US Federal Court dismisses cancer linkage associated with Zantac
The current ruling will assure the safety of the use of Ranitidine for Indian patients
The current ruling will assure the safety of the use of Ranitidine for Indian patients
The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents
48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response
GMP-compliant documentation of all manufacturing steps for cell and gene therapies
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness
Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial
Subscribe To Our Newsletter & Stay Updated
